Efficacy of Pioglitazone on Myocardial Function in Patients Undergoing Coronary Stent Implantation.

Coronary Artery Disease Clinical Trial

Official title:

Pilot Trial Studying the Effects of Pioglitazone in Comparison to Placebo on Myocardial Function and Oxidative Stress in Patients With Type II Diabetes and Insulin Resistance Undergoing Elective PTCA. A Randomized Double-blinded Phase II Study.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00771004
• Other study ID #: ATS K021
• Secondary ID: 2006-002237-20D-
• Status: Completed
• Phase: Phase 2
• First received: October 9, 2008
• Last updated: July 1, 2010
• Start date: August 2006
• Est. completion date: February 2009

Study information

• Verified date: July 2010
• Source: Takeda
• Contact: n/a
• Is FDA regulated: No
• Health authority: European Union: European Medicines Agency
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the effects of pioglitazone, once daily (QD), on heart functioning before, during and after stent implantation.

Description:

Type 2 diabetes increases the risk of coronary heart disease at least by two to three fold compared with non-diabetic subjects. Moreover, prospective studies have shown a significant correlation between several glycemic confounders and morbidity from coronary heart disease even in patients without diabetes mellitus. In patients with previously diagnosed coronary heart disease, impaired glucose tolerance was found in 30 to 67 %. The cardiovascular risk of patients with insulin resistance, with or without glucose intolerance has become more and more apparent within recent years and quantitative coronary angiographic studies have revealed a correlation between the severity of coronary heart disease and impaired glucose tolerance.

A new pharmaceutical class for the intervention of insulin resistance, the peroxisome proliferator activated receptor (gamma) agonists have been successfully introduced in the treatment of type 2 diabetes. Beyond their metabolic effects on glucose and lipid metabolism, peroxisome proliferator activated receptor (gamma) agonists show to exert a couple of pleiotropic, anti-inflammatory and vasoprotective effects in patients with type 2 diabetes and impaired glucose tolerance.

The incidence and severity of peri-procedural myocardial injury during percutaneous coronary interventions with stent implantation in diabetic and in non-diabetic patients is an important prognostic confounder for the patient. Different laboratory biomarkers have been investigated as diagnostic tools for the estimation of the risk of peri-procedural myocardial injury. Recent studies have convincingly demonstrated that the risk of subsequent ischemic heart events is related to the extent of cardiac troponin or CK-MB increase after coronary intervention, and the prognosis for these individuals is usually worse than that for patients who do not develop an increase in these biomarkers.

In a recent trial it was shown that pretreatment with atorvastatin could reduce procedural myocardial injury in elective coronary intervention. The incidence of Troponin I increase was 48% in the placebo group compared to 20% in the atorvastatin group.

The aim of this study is to investigate the effect of pioglitazone on the incidence of peri-procedural myocardial injury in patients undergoing percutaneous coronary interventions with stent implantation. Total participation time is anticipated to be 3 weeks.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 63
• Est. completion date: February 2009
• Est. primary completion date: February 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Stable coronary artery disease with planned percutaneous coronary intervention with stent implantation.

• Type II-diabetics and/or an IRIS II score greater than or equal to 50 (measure for the identification of patients with insulin resistance and increased vascular risk).

• Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study.

Exclusion Criteria:

• A planned percutaneous coronary intervention with stent implantation less than 15 days after the screening visit.

• Planned multi-vessel intervention.

• Use of systemic corticosteroids within the last 3 months prior to screening visit.

• Anamnestic history of hypersensitivity to the study drugs or to drugs with similar chemical structures.

• History of severe or multiple allergies.

• Treatment with any other investigational drug within 3 months before trial entry or earlier participation in the present study.

• Have had more than one unexplained episode of severe hypoglycemia (defined as requiring assistance of another person due to disabling hypoglycemia) within 6 months prior to screening visit.

• Progressive fatal disease.

• History of drug or alcohol abuse within the last 10 years.

• A history of significant cardiovascular (New York Health Association stage II - IV), respiratory, gastrointestinal, hepatic (alanine aminotransferase greater than 2.5 times the normal reference range), renal (creatinine greater than 1.2 mg/dL in women and greater than 1.5 in men and/or glomerular filtration rate less than 45), neurological, psychiatric and/or hematological disease as judged by the Investigator.

• Pre-treatment with peroxisome proliferator-activated receptor (gamma) agonists within the 3 months prior to screening.

• If insulin therapy applicable: initiation of insulin therapy within the last 3 months.

• If statin therapy applicable: change of medication within the last 4 weeks.

• Myocardial infarction within 3 months prior to screening visit.

• Blood donation within last 30 days.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Coronary Artery Disease
• Coronary Disease
• Myocardial Ischemia
• Oxidative Stress
• Type 2 Diabetes

Intervention

Drug:
• Pioglitazone
Pioglitazone 30 mg, tablets, orally, once daily for one week; increased to Pioglitazone 45 mg, tablets, orally, once daily for up to two weeks.
• Placebo
Pioglitazone placebo-matching tablets, orally, once daily for up to three weeks.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Takeda

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of Cardiac Troponin I elevation (greater than 1 upper limit of normal) post-percutaneous coronary intervention with stent implantation.		24 hours post stent implantation.	No
Secondary	Incidence of Creatine Kinase (Myocard-type) post-percutaneous coronary intervention with stent implantation.		24 hours post stent implantation.	No
Secondary	Mean peak values of Troponin I and Creatine Kinase (Myocard-type) post-percutaneous coronary intervention with stent implantation.		Hours: 2, 6 and 12 and 24 post stent implantation.	No
Secondary	Frequency of Doppler-detected microembolism measured by high intensity transient signals during percutaneous coronary intervention with stent implantation (sub-study Jena only).		Duration of stent implantation surgery.	No
Secondary	Time course of Troponin I Laboratory Procedure.		Visits: 2, 3, 4, 5, 6, 7, and 8 or Final Visit.	No
Secondary	Time course of high-sensitive-C-Reactive Peptide Laboratory Procedure.		Visits: 2, 3, 4, 5, 6, 7, and 8 or Final Visit.	No
Secondary	Time course of nitrotyrosine Laboratory Procedure.		Visits: 2, 3, 4, 5, 6, 7, and 8 or Final Visit.	No
Secondary	Time course of Asymmetric dimethylarginine Laboratory Procedure.		Visits: 2, 3, 4, 5, 6, 7, and 8 or Final Visit.	No
Secondary	Time course of E-selectin Laboratory Procedure.		Visits: 2, 3, 4, 5, 6, 7, and 8 or Final Visit.	No
Secondary	Time course of Myoglobin Laboratory Procedure.		Visits: 2, 3, 4, 5, 6, 7, and 8 or Final Visit.	No
Secondary	Time course of Visfatin Laboratory Procedure.		Visits: 2, 3, 4, 5, 6, 7, and 8 or Final Visit.	No
Secondary	Time course of Proinsulin intact Laboratory Procedure.		Visits: 1 and 7 or Final Visit.	No
Secondary	Time course of Adiponectin Laboratory Procedure.		Visits: 1 and 7 or Final Visit.	No

External Links

•   ACTOS® Package Insert
•   FDA Safety Alerts and Recalls